Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3720)
All Articles published online
|
Aug 6, 2012 (publication date) through Dec 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther 2012; 3(4): 62-67 [PMID: 22966484 DOI: 10.4292/wjgpt.v3.i4.62] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v3/i4/62.htm |
| Number | Citing Articles |
| 1 |
E. M. Ledeneva, A. L. Vertkin, Yu. V. Sediakina, N. A. Burakova, M. M. Shamuilova, S. S. Kurdjieva. Management of patients with liver cirrhosis at outpatient stage: How not to miss it?. Medical alphabet 2023; (35): 14 doi: 10.33667/2078-5631-2022-35-14-18
|
| 2 |
Abhishek Basappanamalige Lokesh Reddy, Sabeena Kizhedath, Bindhu Vasudevan. COMPARISON OF RIFAXIMIN, LACTULOSE WITH RIFAXIMIN, LACTULOSE, BRANCHED CHAIN AMINOACIDS (BCAA) IN GRADE 1 TO GRADE 3 OF HEPATIC ENCEPHALOPATHY- NON RANDOMIZED CONTROLLED TRIAL STUDY. Journal of Evolution of Medical and Dental Sciences 2017; 6(74): 5314 doi: 10.14260/Jemds/2017/1153
|
| 3 |
Marcos F. Ocaña-Sánchez, Gabriel A. Soto-Ojeda, Yolanda Cocotle-Ronzón, Cesar Soria-Fregozo, Alberto Sánchez-Medina, Rosa V. García-Rodríguez, Juan F. Rodríguez-Landa, Erick J. Corro-Méndez, Minerva Hernández-Lozano. Flaxseed Oil (Linum usitatissimum) Prevents Cognitive and Motor Damage in Rats with Hyperammonemia. Nutrients 2023; 15(21): 4550 doi: 10.3390/nu15214550
|
| 4 |
Leen Z. Hasan, George Y. Wu. Novel Agents in the Management of Hepatic Encephalopathy: A Review. Journal of Clinical and Translational Hepatology 2021; 0(000): 000 doi: 10.14218/JCTH.2021.00102
|
| 5 |
Yi-Kuan Tseng, Ken-Ning Hsu. Study design for a three-arm equivalence clinical trial with binomially distributed outcomes. Journal of Biopharmaceutical Statistics 2021; 31(6): 736 doi: 10.1080/10543406.2021.1968891
|
| 6 |
Lorenzo Ridola, Angelo Zullo, Cesare Hassan. Rifaximin as treatment for hepatic encephalopathy: Some considerations. Saudi Journal of Gastroenterology 2013; 19(1): 56 doi: 10.4103/1319-3767.105930
|
| 7 |
Halina White. Gastrointestinal Disorders and the Nervous System. CONTINUUM: Lifelong Learning in Neurology 2020; 26(3): 577 doi: 10.1212/CON.0000000000000871
|
| 8 |
Francesca Romana Ponziani, Viviana Gerardi, Silvia Pecere, Francesca D’Aversa, Loris Lopetuso, Maria Assunta Zocco, Maurizio Pompili, Antonio Gasbarrini. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World Journal of Gastroenterology 2015; 21(43): 12322-12333 doi: 10.3748/wjg.v21.i43.12322
|
| 9 |
Hector Ferral, Elisa Gomez-Reyes, Claus J Fimmel. Post–Transjugular Intrahepatic Portosystemic Shunt Follow-Up and Management in the VIATORR Era. Techniques in Vascular and Interventional Radiology 2016; 19(1): 82 doi: 10.1053/j.tvir.2016.01.009
|
| 10 |
Roberto Lorenzetti, Cosimo Prantera. Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results. Clinical Investigation 2013; 3(12): 1187 doi: 10.4155/cli.13.96
|
| 11 |
Daniel Paulson, Mona Shah, Lisa Renee Miller-Matero, Anne Eshelman, Marwan Abouljoud. Cognition Predicts Quality of Life Among Patients With End-Stage Liver Disease. Psychosomatics 2016; 57(5): 514 doi: 10.1016/j.psym.2016.03.006
|
| 12 |
C.E. Coronel-Castillo, J. Contreras-Carmona, A.C. Frati-Munari, M. Uribe, N. Méndez-Sánchez. Eficacia de la rifaximina en los diferentes escenarios clínicos de la encefalopatía hepática. Revista de Gastroenterología de México 2020; 85(1): 56 doi: 10.1016/j.rgmx.2019.09.001
|
| 13 |
Asmaa N. Mohammad, Mahmoud K. Elsamman, Amr M. Zaghloul, Hameda H. Mohamed, Walaa I. Mohammed. Rifaximin plus cefotaxime versus cefotaxime alone in treatment of spontaneous bacterial peritonitis in patients with cirrhosis. The Egyptian Journal of Internal Medicine 2018; 30(3): 154 doi: 10.4103/ejim.ejim_19_18
|
| 14 |
David Kockerling, Rooshi Nathwani, Roberta Forlano, Pinelopi Manousou, Benjamin H Mullish, Ameet Dhar. Current and future pharmacological therapies for managing cirrhosis and its complications. World Journal of Gastroenterology 2019; 25(8): 888-908 doi: 10.3748/wjg.v25.i8.888
|
| 15 |
Natalia Szóstak, Marek Figlerowicz, Anna Philips. The emerging role of the gut mycobiome in liver diseases. Gut Microbes 2023; 15(1) doi: 10.1080/19490976.2023.2211922
|
| 16 |
C.E. Coronel-Castillo, J. Contreras-Carmona, A.C. Frati-Munari, M. Uribe, N. Méndez-Sánchez. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy. Revista de Gastroenterología de México (English Edition) 2020; 85(1): 56 doi: 10.1016/j.rgmxen.2019.09.003
|
| 17 |
E. Bouza, L. Alcalá, M. Marín, M. Valerio, E. Reigadas, P. Muñoz, M. González-Del Vecchio, V. de Egea. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy. European Journal of Clinical Microbiology & Infectious Diseases 2017; 36(10): 1777 doi: 10.1007/s10096-017-2991-y
|
| 18 |
Pallab Ray, Shreya Singh, Swati Gupta. Topical Antimicrobial Therapy: Current Status and Challenges. Indian Journal of Medical Microbiology 2019; 37(3): 299 doi: 10.4103/ijmm.IJMM_19_443
|
| 19 |
R. Ennaifer, N. Elleuch, M. Cheikh, H. Romdhane, H. Ben Nejma, N. Bel Hadj. La rifaximine : une nouvelle alternative dans la prévention des infections bactériennes chez le cirrhotique ?. Journal Africain d'Hépato-Gastroentérologie 2015; 9(3): 122 doi: 10.1007/s12157-015-0606-8
|
| 20 |
Charlotte Skinner, Alex J. Thompson, Mark R. Thursz, Julian R. Marchesi, Nikhil Vergis. Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. Therapeutic Advances in Gastroenterology 2020; 13 doi: 10.1177/1756284820942616
|
| 21 |
Angelo Zullo, Lorenzo Ridola, Cesare Hassan. Rifaximin Therapy and Clostridium difficile Infection. Journal of Clinical Gastroenterology 2013; 47(8): 737 doi: 10.1097/MCG.0b013e31828bea4b
|
| 22 |
|
| 23 |
Jordi Sanchez-Delgado, Mireia Miquel. Papel de la rifaximina en el tratamiento de la encefalopatía hepática. Gastroenterología y Hepatología 2016; 39(4): 282 doi: 10.1016/j.gastrohep.2015.08.003
|
| 24 |
Yuval Ishay, Yotam Kolben, Asa Kessler, Yaron Ilan. Role of circadian rhythm and autonomic nervous system in liver function: a hypothetical basis for improving the management of hepatic encephalopathy. American Journal of Physiology-Gastrointestinal and Liver Physiology 2021; 321(4): G400 doi: 10.1152/ajpgi.00186.2021
|
| 25 |
Khadija A. M. Glal, Sherief M. Abd‐Elsalam, Tarek M. Mostafa. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double‐blind controlled trial. Journal of Hepato-Biliary-Pancreatic Sciences 2021; 28(10): 812 doi: 10.1002/jhbp.947
|
| 26 |
Axel Holstege. Hepatische Enzephalopathie Teil 2: Therapie. Gastroenterologie up2date 2023; 19(04): 357 doi: 10.1055/a-2039-9694
|
| 27 |
Jordi Sanchez-Delgado, Mireia Miquel. Role of rifaximin in the treatment of hepatic encephalopathy. Gastroenterología y Hepatología (English Edition) 2016; 39(4): 282 doi: 10.1016/j.gastre.2016.03.006
|
| 28 |
T. E. Polunina. Risk stratification in alcoholic cirrhosis of the liver: a case study. Meditsinskiy sovet = Medical Council 2023; (8): 126 doi: 10.21518/ms2023-129
|
| 29 |
Motoh Iwasa, Yoshiyuki Takei. Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia. Hepatology Research 2015; 45(12): 1155 doi: 10.1111/hepr.12495
|